BOSTON, MA -- (Marketwired) -- 11/08/17 -- Real world evidence is poised to play a growing…
Continue ReadingTag: biotechnology
Cardiovascular Drug Approval Rate in the U.S. Fell as Development Time Rose, According to the Tufts Center for the Study of Drug Development
BOSTON, MA -- (Marketwired) -- 09/12/17 -- Although the rate at which investigational drugs received marketing…
Continue ReadingAbuse-Deterrent Opioid Development and Uptake Are Tied to Efficacy and Regulatory/Payer Policies, According to the Tufts Center for the Study of Drug Development
BOSTON, MA -- (Marketwired) -- 07/13/17 -- Although 10 new opioid products with abuse-deterrent formulations (ADF)…
Continue ReadingAccelerating Pace of Approvals and a Strong Development Pipeline Indicate Vigorous Growth for New Biotech Products, According to the Tufts Center for the Study of Drug Development
BOSTON, MA -- (Marketwired) -- 05/09/17 -- Biopharmaceuticals accounted for 35% of all new drug approvals…
Continue ReadingSV Life Sciences Changes Name to SV Health Investors to Better Reflect the Firm–s Longstanding Strategy and Focus
BOSTON, MA -- (Marketwired) -- 04/10/17 -- SV Life Sciences has changed its name to ,…
Continue ReadingPoor Physician and Nurse Engagement Contributes to Low Patient Recruitment Rates, According to the Tufts Center for the Study of Drug Development
BOSTON, MA -- (Marketwired) -- 01/11/17 -- Although physicians and nurses are familiar with, and comfortable…
Continue ReadingCost to Develop and Win Marketing Approval for a New Drug Is $2.6 Billion, According to the Tufts Center for the Study of Drug Development
BOSTON, MA -- (Marketwired) -- 11/18/14 -- Developing a new prescription medicine that gains marketing approval,…
Continue Reading